Loading...
Indian Pharmaceutical Exporter · #1 for Mefloquine · $550.0K export value · DGFT Verified
Cipla Limited is the #1 Indian exporter of Mefloquine with $550.0K in export value and 11 verified shipments. Cipla Limited holds a 22.5% market share in Mefloquine exports across 5 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
| BANGLADESH |
| $716 |
| 1 |
| 0.2% |
Cipla Limited exports Mefloquine to 5 countries. The largest destination is CAMBODIA accounting for 44.8% of Cipla Limited's Mefloquine shipments, followed by BRAZIL (29.9%) and PERU (20.6%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| NATIONAL CENTER FOR PARASITOLOGY, E | CAMBODIA | $150.0K | 3 |
| MINISTERIO DA SAUDE DEPARTAMENTO | BRAZIL | $100.0K | 2 |
| MINISTERIO DE SALUD | PERU | $69.1K | 3 |
| CMPE RAI3E MINISTRY OF HEALTH | LAO PEOPLE'S DEMOCRATIC REPUBLIC | $14.9K | 2 |
| D G CENTRAL MEDICAL STORES | BANGLADESH | $716 | 1 |
Cipla Limited supplies Mefloquine to 5 buyers globally. The largest buyer is NATIONAL CENTER FOR PARASITOLOGY, E (CAMBODIA), followed by MINISTERIO DA SAUDE DEPARTAMENTO (BRAZIL) and MINISTERIO DE SALUD (PERU). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
India exported $907.4K worth of Mefloquine through 265 shipments from 75 suppliers to 56 countries, serving 118 buyers globally. Cipla Limited contributes $550.0K to this total, accounting for 22.5% of India's Mefloquine exports. Cipla Limited ships Mefloquine to 5 countries through 5 buyers.
Cipla Limited's average Mefloquine shipment value is $50.0K per consignment, based on 11 shipments totaling $550.0K. The largest destination is CAMBODIA (44.8% of Cipla Limited's Mefloquine exports).
Cipla Limited ranks #1 among 75 Indian Mefloquine exporters with a 22.5% market share. The top 3 exporters are CIPLA LIMITED ($550.0K), KALINDI OVERSEAS ($116.7K), YASHICA PHARMACEUTICALS PRIVATE LIMITED ($83.0K). Cipla Limited processed 11 shipments to 5 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| ARTESUNATE 100MG+MEFLOQUINE 200MG TABLET | $334.7K | 11 |
Cipla Limited exports 1 distinct Mefloquine formulations including tablets, capsules, syrups, and combination drugs. The top formulation is ARTESUNATE 100MG+MEFLOQUINE 200MG TABLET with 11 shipments worth $334.7K.
What Cipla Limited must comply with to export Mefloquine to its top destination countries
Approval Process
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Exporters ranked immediately above and below #1 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | CIPLA LIMITED ★ | $550.0K | 11 | 5 | $50.0K |
| 2 | KALINDI OVERSEAS | $116.7K | 22 | 6 | $5.3K |
| 3 | YASHICA PHARMACEUTICALS PRIVATE LIMITED | $83.0K | 8 | 5 | $10.4K |
Cipla Limited ranks #1 among 75 Indian Mefloquine exporters. Average shipment value of $50.0K compared to the market average of $12.1K. The closest competitors by value are KALINDI OVERSEAS and YASHICA PHARMACEUTICALS PRIVATE LIMITED.
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 107 | 40.4% |
| SAHAR AIR | 59 | 22.3% |
| Bombay Air | 20 | 7.5% |
| DELHI AIR | 12 | 4.5% |
| Bombay Air Cargo | 12 | 4.5% |
| AHEMDABAD AIR | 8 | 3.0% |
| Delhi Air | 7 | 2.6% |
| DELHI AIR CARGO ACC (INDEL4) | 5 | 1.9% |
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
Cipla Limited exports 98 products worth $1.1B. Beyond Mefloquine, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Mefloquine — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Verify manufacturer licensing and export certifications with the official agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 56+ countries, 118+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Mefloquine exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Mefloquine. For current shipment-level data, contact TransData Nexus.